Talphera, Inc. TLPH
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -7.89%
- 1 year
- -17.97%
- Market cap
- 54.50M
- Revenue (ttm)
- 398.00K
- EPS (ttm)
- -0.26
- Shares out
- 17.03M
- Forward P/E
- -0.63
- YTD return
- -7.89%
- 1-year return
- -17.97%
- Volume
- 92.48K
- Avg volume
- 171.53K
- Open
- 1.01
- Previous close
- 1.04
- Day's range
- 1.01 – 1.06
- 52-week range
- 0.69 – 1.57
- Beta
- 0.30
- Price target
- 4.17 (+296.8%)
1M -0.11 (-9.48%)
Key statistics
- Enterprise value
- 3.76M
- PEG ratio
- 0.00
- Price / sales
- 26.23
- Price / book
- 0.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.63M
- Total cash
- 14.02M
- Total debt
- 6.53M
- Return on equity
- -118.40%
- Short % of float
- 0.67%
- 50-day average
- 0.8056
- 200-day average
- 0.93205
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 4.17
- Target (high)
- 6.00
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.20 | -0.13 | +0.07 | +35.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.22 | -0.15 | +0.07 | +31.82% |
| May 14, 2024 | Mar 1, 2024 | -0.28 | -0.16 | +0.12 | +42.86% |
| Mar 6, 2024 | Dec 1, 2023 | -0.24 | -0.25 | -0.01 | -4.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 6, 2024 | Maxim Group | init | — | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 22, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 7, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Talphera, Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- talphera.com
News
Your note
Sign in to keep a note on TLPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS ADRIAN | Director | Stock Award(Grant) | Jun 23, 2024 | 13,342 |
| ANGOTTI VINCENT J | Chief Executive Officer | Purchase | Dec 4, 2024 | 208,066 |
| ASADORIAN RAFFI | Chief Financial Officer | Sale | Dec 1, 2024 | 37,578 |
| BOZILENKO MARINA | Director | Stock Award(Grant) | Jun 23, 2024 | 4,780 |
| BROADFOOT JILL MARIE | Director | Stock Award(Grant) | Jun 23, 2024 | 4,280 |
| DASU BADRI N | Officer | Stock Award(Grant) | Feb 13, 2024 | 31,820 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 11.70% | 1,992,519 | 1.22M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 4.46% | 758,966 | 465.25K | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 1.86% | 316,460 | 193.99K | Sep 29, 2024 |
| MAI Capital Management | 1.66% | 282,342 | 173.07K | Sep 29, 2024 |
| Vanguard Group Inc | 1.42% | 240,970 | 147.71K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.91% | 155,495 | 95.32K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.94% | 159,612 | 97.84K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.57% | 97,092 | 59.52K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.48% | 81,358 | 49.87K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 22,889 | 14.03K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.10% | 16,366 | 10.03K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 15,764 | 9.66K | Oct 30, 2024 |